Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Functional Consequences of T-bet Expression After LAIV
NCT04080245Phase 1Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Nov 2019
- Primary completion
- Jun 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of live attenuated influenza vaccine in influenza, sponsored by University of Alabama at Birmingham. Primary endpoint: Participants with a positive T-bet expressing Flu-specific B cell subtype. Started Nov 2019; status: completed.
02
Drugs
live attenuated influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT04080245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04080245.